Ungulates with genetically modified immune systems
The present invention provides ungulate animals, tissue and organs as well as cells and cell lines derived from such animals, tissue and organs, which lack expression of functional endogenous immunoglobulin loci. The present invention also provides ungulate animals, tissue and organs as well as cells and cell lines derived from such animals, tissue and organs, which express xenogenous, such as human, immunoglobulin loci. The present invention further provides ungulate, such as porcine genomic DNA sequence of porcine heavy and light chain immunogobulins. Such animals, tissues, organs and cells can be used in research and medical therapy. In addition, methods are provided to prepare such animals, organs, tissues, and cells.
1. A transgenic porcine animal whose genome comprises a homozygous disruption of nucleotides 3296-3352 of SEQ ID NO: 29 of the joining region (J region) of the endogenous porcine heavy chain gene, wherein the porcine lacks expression of the endogenous porcine heavy chain immunoglobulin gene.
2. The transgenic porcine of claim 1 , wherein the porcine animal comprises a homozygous disruption of the constant region of the endogenous porcine kappa immunoglobulin gene, wherein the disruption results in a lack of expression of the endogenous kappa immunoglobulin gene.
3. The porcine of claim 1 , wherein the porcine heavy chain gene is disrupted through substitution, deletion or insertion techniques.
4. The porcine of claim 3 , wherein the porcine heavy chain gene is disrupted through site specific recombinase techniques.
5. The porcine of claim 1 , wherein the homozygous disruption is produced by homologous recombination.
6. The porcine of claim 1 , wherein the porcine expresses a xenogenous immunoglobulin locus or fragment thereof and wherein the immunoglobulin is expressed from an immunoglobulin locus that is integrated within an endogenous porcine chromosome.
7. The porcine of claim 6 , wherein the xenogenous immunoglobulin comprises a human immunoglobulin or fragment thereof.
8. The porcine of claim 6 , wherein the xenogenous immunoglobulin locus is inherited by offspring.
9. The porcine of claim 6 , wherein the xenogenous immunoglobulin locus is inherited through the male germ line by offspring.
10. The porcine of claim 6 , wherein the porcine is produced through nuclear transfer.
11. The porcine of claim 6 , wherein the immunoglobulin locus is expressed in B cells to produce xenogenous immunoglobulin in response to exposure to one or more antigens.
12. The porcine of claim 1 , further comprising an additional genetic modification to eliminate the expression of a xenoantigen.
13. The porcine of claim 12 , wherein the xenoantigen is alpha-1,3-galactosyltransferase.
14. The transgenic porcine of claim 2 , wherein the porcine animal comprises a homozygous disruption of the constant region of the endogenous porcine lambda immunoglobulin gene, wherein the disruption results in the lack of expression of the endogenous porcine lambda immunoglobulin gene.
15. The porcine of claim 14 , wherein the porcine heavy chain, kappa light chain and lambda light chain genes can be transcribed into RNA but not translated into protein.
16. The porcine of claim 14 , wherein the porcine heavy chain, kappa light chain and lambda light chain genes are inactivated such that no transcription of the genes occurs.
17. The porcine of claim 14 , wherein the porcine heavy chain, kappa light chain and lambda light chain genes are inactivated such that they are transcribed and then translated into non-functional proteins.
18. The porcine of any one of claims 1 - 14 , wherein the porcine is produced by nuclear transfer.
19. Isolated cells derived from the porcine of claim 1 .
20. Isolated A tissue derived from the porcine of claim 1 .